See more : Mallcom (India) Limited (MALLCOM.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Freeline Therapeutics Holdings plc (FRLN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Freeline Therapeutics Holdings plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Transformers and Rectifiers (India) Limited (TRIL.BO) Income Statement Analysis – Financial Results
- CGN Power Co., Ltd. (003816.SZ) Income Statement Analysis – Financial Results
- Stella International Holdings Limited (1836.HK) Income Statement Analysis – Financial Results
- NKGen Biotech, Inc. Common Stock (NKGN) Income Statement Analysis – Financial Results
- Progyny, Inc. (PGNY) Income Statement Analysis – Financial Results
Freeline Therapeutics Holdings plc (FRLN)
About Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.74M | 2.39M | 1.93M | 1.55M | 0.00 |
| Gross Profit | -1.74M | -2.39M | -1.93M | -1.55M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 66.20M | 95.43M | 76.15M | 47.04M | 34.19M |
| General & Administrative | 30.66M | 44.57M | 26.30M | 16.60M | 6.79M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.66M | 44.57M | 26.30M | 16.60M | 6.79M |
| Other Expenses | -1.57M | -2.09M | -15.27M | -10.60M | -390.00K |
| Operating Expenses | 95.29M | 137.91M | 87.18M | 53.05M | 32.72M |
| Cost & Expenses | 95.29M | 137.91M | 87.18M | 53.05M | 32.72M |
| Interest Income | 904.00K | 403.95K | 275.00K | 74.31K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 151.00K |
| Depreciation & Amortization | 1.27M | 9.24M | 17.18M | 12.14M | 970.00K |
| EBITDA | -97.17M | -133.14M | -85.27M | -51.51M | -32.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -98.45M | -142.38M | -102.45M | -63.64M | -40.98M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.84M | 2.33M | 6.26M | 9.88M | -470.80K |
| Income Before Tax | -88.60M | -140.05M | -96.19M | -53.77M | -33.26M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 368.00K | 342.00K | 129.00K | 141.00K | 27.00K |
| Net Income | -88.97M | -140.39M | -96.32M | -53.91M | -33.28M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -22.52 | -58.98 | -102.09 | -127.39 | -78.65 |
| EPS Diluted | -22.52 | -58.98 | -102.09 | -127.39 | -78.65 |
| Weighted Avg Shares Out | 3.95M | 2.38M | 943.52K | 423.19K | 423.19K |
| Weighted Avg Shares Out (Dil) | 3.95M | 2.38M | 943.52K | 423.19K | 423.19K |
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease
Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
Freeline to Participate in Upcoming Investor Conferences
Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease
New Strong Buy Stocks for July 14
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Freeline to Present at 2023 Jefferies Healthcare Conference
Freeline to Present at 22nd Annual Needham Virtual Healthcare Conference
Freeline to Present at the Stifel Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports